Background There was a complete lack of information about the treatment outcomes of
rifampicin/multidrug resistant (RR/MDR) childhood TB patients (age≤ 14 years) from …

Background: Significant data gaps exist for children and adolescents with drug-resistant
(DR) TB, particularly from high TB incidence settings. This report provides a descriptive …

Optimal diagnosis and management of children aged< 15 y with rifampicin-or multidrug-
resistant tuberculosis (RR/MDR-TB) relies on identification of adults with the disease and …

Background We aimed to compare and contrast the proportions of treatment outcome
between developing and developed countries in children treated for multidrug resistance …

Objective Pakistan has a high pediatric burden of tuberculosis, but few studies describe the
treatment experience of children with tuberculosis in Pakistan. We sought to identify risk …

Background Few studies have described the management of multidrug-resistant (MDR)
tuberculosis (TB) in children and evidence-based guidance on management is lacking. We …

Abstract Approximately 25,000 children develop multidrug-resistant (MDR) tuberculosis (TB)
each year, but few of them are diagnosed and appropriately treated for MDR-TB. New …

SETTING: Médecins Sans Frontières (MSF) clinic in Mumbai, India. OBJECTIVE: To
determine the final treatment outcomes, culture conversion and adverse events (AEs) during …

BACKGROUND: The treatment of rifampicin-resistant TB (RR-TB) in children is evolving
rapidly. As newer regimens are introduced into routine care, it is vital to compare their …

OBJECTIVE: To describe the demographic and clinical characteristics of children and
adolescents diagnosed with resistance to any anti-tuberculosis drug (drug-resistant …